Considering human challenge trials for tuberculosis vaccine development. Issue 2 (21st January 2022)

• Record Type: Journal Article
• Authors: Kleinwaks, Gavriel; Schmit, Virginia; Morrison, Josh
• Is Part Of: Vaccine. Volume 40:Issue 2(2022)
• Page Start: 173
• Page End: 174
• Publication Date: 2022-01-21
• Subjects: Challenge trial -- Tuberculosis vaccine -- Controlled human infection model; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.11.024
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Human challenge trials provide a promising route to cut down on the high, sometimes prohibitive, costs of vaccine development. By requiring fewer participants than a conventional clinical trial and reducing the time required for a trial, human challenge trials improve economic feasibility and reduce the risk of vaccine development. Tuberculosis is one disease where challenge trials could be very impactful, given that it is a widespread and dangerous disease that is nonetheless difficult to track in a standard clinical vaccine trial. Various attenuated strains of Mycobacterium tuberculosis are in development and can be used in a challenge trial in order to reduce the risk to challenge trial participants and their surrounding communities.